Publikation
Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone
Wissenschaftlicher Artikel/Review - 11.08.2014
Leibowitz-Amit Raya, Alimohamed Nimira, Vera-Badillo Francisco E, Seah Jo-An, Templeton Arnoud, Knox Jennifer J, Tannock Ian F, Sridhar Srikala S, Joshua Anthony M
Bereiche
PubMed
DOI
Zitation
Art
Zeitschrift
Veröffentlichungsdatum
eISSN (Online)
Seiten
Kurzbeschreibung/Zielsetzung
BACKGROUND
Abiraterone acetate (AA), oral CYP17 inhibitor, is an active agent in the treatment of metastatic castrate-resistant prostate cancer (mCRPC).
METHODS
We (R.L.A and N.A) retrospectively evaluated outcome in 12 men who were re-treated with AA following prior treatment with AA at the Princess Margaret Cancer Centre.
RESULTS
All men were heavily pre-treated for mCRPC with a median of four prior lines of therapy, one of which was AA (given either pre- or post-chemotherapy). Eleven out of 12 (92%) men stopped their first treatment course of AA due to progression and one stopped for financial reasons. Seven men had a PSA decrease ≥50% following their first AA treatment, of which three (46%) had a PSA decrease ≥50% to AA re-treatment. The responses to AA re-treatment were generally short-lived with a median biochemical progression-free survival of 2.3 months and median treatment duration of 3.2 months. No PSA responses to AA re-treatment were seen in five men who did not have an initial PSA response to AA.
CONCLUSIONS
Our data suggest that AA re-challenge may have limited benefit in select men with mCRPC, and warrants further formal research.